Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.

Autor:	Saydam G; Department of Internal Diseases, Division of Hematology, Ege University Medical Faculty Hospital, Izmir, 35100, Turkey., Unal A; Department of Internal Diseases, Division of Hematology, Erciyes University Faculty of Medicine, Kayseri, 38030, Turkey., Haznedaroglu IC; Department of Internal Diseases, Division of Hematology, Hacettepe University Faculty of Medicine, Ankara, 06230, Turkey., Hacihanifioglu A; Department of Internal Diseases, Division of Hematology, Kocaeli University Faculty of Medicine, Izmit, 41001, Turkey., Mehtap O; Department of Internal Diseases, Division of Hematology, Kocaeli University Faculty of Medicine, Izmit, 41001, Turkey., Kurtoglu E; Department of Internal Diseases, Division of Hematology, University of Health Sciences, Antalya Training & Research Hospital, Antalya, 07100, Turkey., Gocer M; Department of Internal Diseases, Division of Hematology, University of Health Sciences, Antalya Training & Research Hospital, Antalya, 07100, Turkey., Turgut M; Department of Internal Diseases, Division of Hematology, Ondokuz Mayis University Faculty of Medicine, Samsun, 55139, Turkey., Kelkitli E; Department of Internal Diseases, Division of Hematology, Ondokuz Mayis University Faculty of Medicine, Samsun, 55139, Turkey., Atay MH; Department of Internal Diseases, Division of Hematology, Ondokuz Mayis University Faculty of Medicine, Samsun, 55139, Turkey., Guler N; Department of Internal Diseases, Pamukkale University Faculty of Medicine, Denizli, 20160, Turkey., Koluman BU; Department of Internal Diseases, Pamukkale University Faculty of Medicine, Denizli, 20160, Turkey., Sonmez M; Department of Internal Diseases, Division of Hematology, Karadeniz Technical University Faculty of Medicine, Trabzon, 61080, Turkey., Erkut N; Department of Internal Diseases, Division of Hematology, Karadeniz Technical University Faculty of Medicine, Trabzon, 61080, Turkey., Kaya E; Department of Internal Diseases, Division of Hematology, Inonu University Faculty of Medicine, Malatya, 44280, Turkey., Kuku I; Department of Internal Diseases, Division of Hematology, Inonu University Faculty of Medicine, Malatya, 44280, Turkey., Erkurt MA; Department of Internal Diseases, Division of Hematology, Inonu University Faculty of Medicine, Malatya, 44280, Turkey., Ozet G; Department of Hematology, Ankara City Hospital, Ankara, 06800, Turkey.; Department of Internal Diseases, Ankara Yıldırım Beyazit University Faculty of Medicine, Ankara, 06800, Turkey., Ceran F; Department of Hematology, Ankara City Hospital, Ankara, 06800, Turkey., Sahin F; Department of Internal Diseases, Division of Hematology, Ege University Medical Faculty Hospital, Izmir, 35100, Turkey., Soyer N; Department of Internal Diseases, Division of Hematology, Ege University Medical Faculty Hospital, Izmir, 35100, Turkey., Nalcaci M; Department of Internal Diseases, Istanbul University Istanbul Faculty of Medicine, Istanbul, 34093, Turkey., Yilmaz M; Department of Internal Diseases, Division of Hematology, SANKO University Faculty of Medicine, Gaziantep, 27090, Turkey., Bozkurt S; Department of Medical Oncology, Pfizer Pharmaceuticals, Istanbul, 34394, Turkey., Aver B; Department of Medical Oncology, Pfizer Pharmaceuticals, Istanbul, 34394, Turkey., Ozdengulsun B; Department of Medical Oncology, Pfizer Pharmaceuticals, Istanbul, 34394, Turkey., Ozbilgili E; Department of Medical Oncology, Pfizer Pharmaceuticals, Istanbul, 34394, Turkey., Ilhan O; Department of Internal Diseases, Division of Hematology, Ankara University Faculty of Medicine, Ankara, 06230, Turkey.
Jazyk:	angličtina
Zdroj:	International journal of hematologic oncology [Int J Hematol Oncol] 2022 Jun 30; Vol. 11 (3), pp. IJH40. Date of Electronic Publication: 2022 Jun 30 (Print Publication: 2022).
DOI:	10.2217/ijh-2021-0008
Abstrakt:	Aim: This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey. Materials & Methods: Hospital records between 2005 and 2018 were retrospectively reviewed. Results: Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival. Conclusion: The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients. (© 2022 Guray Saydam.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu